Clinical trials: Plaque, Amyloid
Subjective Memory Loss in Older Persons
Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints
The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels of substances in the blood that may be associated with thinking ability and the health of brain cells in subjects with memory concerns…
- Trial name
- NCT00597376
- Testing
- Cerefolin NAC (a medical food)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Rush University Medical Center
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Gingivitis, Plaque
Measuring Efficacy of an Oral-Irrigator After Three Weeks of Use
The primary objective of this exploratory study is to evaluate the efficacy of an Oral Irrigator in the reduction of gingivitis compared to a negative control over a 3 week period by using the Modified Gingival Index and the…
- Trial name
- NCT04899440
- Testing
- Water Flosser, Control
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Alzheimer's Disease, Mild Cognitive Impairment
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination.
- Trial name
- NCT02309723
- Testing
- Beta amyloid imaging
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Periodontal Diseases
Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical and Surgical Treatment of Teeth With Periodontal Disease
The purpose of this study is to compare clinical outcomes after mechanical debridement of at sites exhibiting plaque induced inflammation with or without adjunctive Antimicrobial photodynamic therapy (aPDT) and to assess the the…
- Trial name
- NCT05252000
- Testing
- mechanical debridement, adjunctive aPDT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson's Disease
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients…
- Trial name
- NCT00857532
- Testing
- florbetapir F 18
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Avid Radiopharmaceuticals
Insomnia
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
The objective of this study is to compare the efficacy of a sleep intervention on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in…
- Trial name
- NCT03954210
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
- Trial name
- PROSE (NCT02752776)
- Testing
- Secukinumab
- Where
- 215 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 1,660 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantar Psoriasis, Plaque Psoriasis
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
- Trial name
- NCT04720105
- Testing
- Duobrii®
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Gingivitis
Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health
The purpose of this study is to evaluate the safety and efficacy of tooth and interproximal cleaning modalities with and without chemistry on oral health over 28 days.
- Trial name
- NCT02187016
- Testing
- AirFloss + BreathRx, AirFloss + Listerine, Dental Floss
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Philips Oral Healthcare
Plaque, Inflammation
Trial of Toothpaste to Reduce Plaque and Inflammation
Dental plaque causes caries and periodontal disease and data are sparse about toothpaste and plaque removal. Inflammation, caused by dental plaque, is a risk factor for cardiovascular disease.
- Trial name
- NCT02666508
- Testing
- Plaque identifying toothpaste, Non-plaque identifying toothpaste
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease, Atherosclerosis
The Lipid-Rich Plaque Study
The purpose of this study is to enhance medical knowledge of the causes of future coronary problems. Many studies in patients who have already experienced a coronary problem point to the danger associated with plaques that are…
- Trial name
- LRP (NCT02033694)
- Testing
- NIRS-IVUS Imaging (TVC Imaging System)
- Where
- 41 sites in United States, Italy and 4 more
- Volunteers
- 1,563 people
- Sponsor
- Infraredx
Acute Coronary Artery Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT02347098)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- VA Office of Research and Development
Psoriasis, Plaque-type Psoriasis
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo.
- Trial name
- NCT01537432
- Testing
- secukinumab
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Atherosclerosis
Aliskiren Effect on Aortic Plaque Progression
This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta.
- Trial name
- ALPINE (NCT01417104)
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ohio State University
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD